HOME >> BIOLOGY >> NEWS
Cancerous vs. healthy cells: Researchers identify the road to success

WASHINGTON, D.C. − Conventional cancer treatments are generally effective in wiping out tumor cells, but in the process they also may kill healthy cells. Researchers are focusing their efforts now on treatments that can target just the cancerous cells, without harming healthy tissue in their midst. These new types of drugs are known as targeted therapies, and physicians are studying their effectiveness and possible side effects in a variety of different types of cancer.

Several targeted therapies are being studied alone and in combination to treat a variety of cancer types. In particular, cancerous brain tumors can be more difficult to treat than other cancers, and oncologists are developing therapies that target these cells to improve patients' survival. Researchers also are gaining a better understanding of the molecular differences between cancerous and healthy cells, improving current treatment and survival rates, according to studies presented today at the 97th Annual Meeting of the American Association for Cancer Research.

NF-kB as a Therapeutic Target in Malignant Gliomas: Abstract No. 1506

Researchers from the National Cancer Institute in Bethesda, Md., have found they may be able to successfully treat brain tumor cells with a new targeted therapy that inhibits the activity of a cell protein called nuclear factor-Kappa B (NF-kB).

The drug, called bortezomib or (Velcade) when used alone or in combination with other cancer treatments represents a potential new way to treat malignant glioma, a particularly stubborn and aggressive brain tumor.

"Targeting the NF-kB pathway either alone or in combination with other chemotherapy agents, is an effective anti-glioma treatment," said Ai-Min Hui, M.D., Ph.D., research fellow at the NCI and the lead investigator of the study.

In their study, the NCI researchers set out to determine the role of NF-kB in reversing the apoptotic (or programmed cell dea
'"/>

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
7-Apr-2006


Page: 1 2 3 4 5 6

Related biology news :

1. Cancerous or harmless? Three genes might tell the tale
2. Cell damage caused by brushing may help keep gums healthy
3. New research shows vaginal bacteria vary among healthy women, need customized treatment
4. Children born after PGD as healthy as those born after conventional IVF treatment
5. University of Pittsburgh discovers genetic shut down trigger in healthy immune cells
6. Study to probe how healthy younger adults make use of genetic tests
7. Strawberry daiquiris -- the extra-healthy cocktail?
8. Novel strategies for healthy aging
9. Study to look at aspirin as aid to conception, healthy pregnancy
10. Air contaminants databases ease healthy homes planning
11. OHSU studies of technology for healthy aging get boost

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader ... Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. ... in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply ...
(Date:6/25/2020)... , ... June 24, 2020 , ... ... enterprise software and software-driven clinical data services that accelerate drug development, is collaborating ... selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the ...
(Date:6/23/2020)... ... 23, 2020 , ... Rigaku Corporation , a global ... a series of TOPIQ webinars, which will cover the Transferable Aspherical Atom Model ... response to social distancing measures that resulted in postponements and cancelations of global ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a leading ... food industries, is pleased to announce that Charles Galea has joined its clinical ... Charles is an accomplished and results-driven sales executive with over 10 years of ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license to ... move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT ... Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: ... hosted an elite awards program, highlighting outstanding examples of how technology innovations and ...
Breaking Biology Technology:
Cached News: